Dyne Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in three major upcoming investor conferences. The company will participate in fireside chats at the Guggenheim Inaugural Healthcare Innovation Conference on November 13 in Boston, the Stifel 2024 Healthcare Conference on November 19 in New York, and the Piper Sandler 36th Annual Healthcare Conference on December 3 in New York. Live webcasts of all presentations will be available on Dyne's website, with replays accessible for 90 days.

News Market Reaction

-2.70%

1 alert

-2.70% News Effect

On the day this news was published, DYN declined 2.70%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

• Guggenheim Inaugural Healthcare Innovation Conference, fireside chat on Wednesday, November 13, 2024 at 4:00 p.m. ET in Boston
  
• Stifel 2024 Healthcare Conference, fireside chat on Tuesday, November 19, 2024 at 3:00 p.m. ET in New York
  
• Piper Sandler 36^th Annual Healthcare Conference, fireside chat on Tuesday, December 3, 2024 at 3:00 p.m. ET in New York
  

A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

What investor conferences will Dyne Therapeutics (DYN) attend in late 2024?

Dyne Therapeutics will attend three conferences: Guggenheim Inaugural Healthcare Innovation Conference on November 13, Stifel 2024 Healthcare Conference on November 19, and Piper Sandler 36th Annual Healthcare Conference on December 3, 2024.

Where can I watch Dyne Therapeutics (DYN) investor conference presentations?

Live webcasts of Dyne's presentations will be available in the Investors & Media section of their website at investors.dyne-tx.com, with replays accessible for 90 days.

What type of presentations will Dyne Therapeutics (DYN) give at the 2024 healthcare conferences?

Dyne Therapeutics will participate in fireside chat presentations at all three conferences.

Which cities will host Dyne Therapeutics (DYN) investor presentations in late 2024?

The presentations will take place in Boston (Guggenheim Conference) and New York (Stifel and Piper Sandler Conferences).